PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 23463181-1 2013 OBJECTIVE: We investigated whether dexmedetomidine provided protective effects on cecal ligation and puncture (CLP)-induced septic mice, through suppressing the expression of pro-inflammatory cytokines [tumor necrosis factor-alpha (TNF-alpha) and interlukin-6 (IL-6)] and high mobility group box 1 (HMGB1). Dexmedetomidine 35-50 tumor necrosis factor Mus musculus 203-230 23463181-1 2013 OBJECTIVE: We investigated whether dexmedetomidine provided protective effects on cecal ligation and puncture (CLP)-induced septic mice, through suppressing the expression of pro-inflammatory cytokines [tumor necrosis factor-alpha (TNF-alpha) and interlukin-6 (IL-6)] and high mobility group box 1 (HMGB1). Dexmedetomidine 35-50 tumor necrosis factor Mus musculus 232-241 23463181-5 2013 Serum concentrations of IL-6 and TNF-alpha decreased significantly in dexmedetomidine administration groups compared with the CLP group. Dexmedetomidine 70-85 tumor necrosis factor Mus musculus 33-42 34625874-8 2022 Compared with I/R group, Dex and Oxy treatment down-regulated the expression of NF-kappaB, TLR4, TNF-alpha and CD68 (all p < 0.05), while no significantly different was found in CD206 and IL-10. Dexmedetomidine 25-28 tumor necrosis factor Mus musculus 97-106 34747306-9 2021 The MPO activity and inflammatory cytokines (tumor necrosis factor-alpha, interleukin-1beta, and NLR family pyrin domain-containing 3) levels were also significantly reduced after DEX treatment compared with those in the ALI mice. Dexmedetomidine 180-183 tumor necrosis factor Mus musculus 45-72 22092133-9 2011 Both pre- and post-treatment with dexmedetomidine markedly reduced lung edema and inflammatory response and lowered MPO activity and ICAM-1 and TNF-alpha mRNA expression. Dexmedetomidine 34-49 tumor necrosis factor Mus musculus 144-153 33821300-5 2021 RESULTS: DEX significantly inhibited LPS-induced increases in the lung weight/body weight ratio and lung wet/dry weight ratio, decreased inflammatory cell infiltration, and decreased the production of proinflammatory factors, such as interleukin-1beta (IL-1beta), IL-6, and tumor necrosis factor alpha (TNF-alpha)in the lungs. Dexmedetomidine 9-12 tumor necrosis factor Mus musculus 274-301 33821300-5 2021 RESULTS: DEX significantly inhibited LPS-induced increases in the lung weight/body weight ratio and lung wet/dry weight ratio, decreased inflammatory cell infiltration, and decreased the production of proinflammatory factors, such as interleukin-1beta (IL-1beta), IL-6, and tumor necrosis factor alpha (TNF-alpha)in the lungs. Dexmedetomidine 9-12 tumor necrosis factor Mus musculus 303-312 34421084-7 2021 Dex inhibited the inflammatory response through decreasing the release and the mRNA expression of IL-1beta, IL-6, and TNF-alpha while increasing that of IL-10. Dexmedetomidine 0-3 tumor necrosis factor Mus musculus 118-127 34692497-8 2021 In the Dexmedetomidine group, cortisol levels were lower on POD 3 (P=0.004) and TNF-alpha levels were lower at 4 weeks after surgery (P<0.001) compared to the Control group. Dexmedetomidine 7-22 tumor necrosis factor Mus musculus 80-89 34278508-7 2021 The results showed that DEX treatment markedly increased the survival rate and neurological score, increased neuron survival, decreased the expression of the LC3, Beclin-1 and NF-kappaB proteins, as well as the cytokines IL-1beta, IL-6 and TNF-alpha, which indicated that DEX-mediated inhibition of autophagy and neuroinflammation ameliorated neuronal death following TBI. Dexmedetomidine 24-27 tumor necrosis factor Mus musculus 240-249 34278508-7 2021 The results showed that DEX treatment markedly increased the survival rate and neurological score, increased neuron survival, decreased the expression of the LC3, Beclin-1 and NF-kappaB proteins, as well as the cytokines IL-1beta, IL-6 and TNF-alpha, which indicated that DEX-mediated inhibition of autophagy and neuroinflammation ameliorated neuronal death following TBI. Dexmedetomidine 272-275 tumor necrosis factor Mus musculus 240-249 34172807-5 2021 We found that DEX treatment reduced the expression of CD68, iNOS, TNF-alpha, and IL-1beta, and increased the expression of CD206, Arg1, IL-10 and TGF-beta in microglia, ameliorating heatstroke induced neuroinflammation and brain injury in mice. Dexmedetomidine 14-17 tumor necrosis factor Mus musculus 66-75 34451922-8 2021 In animal models, dexmedetomidine inhibited the proliferation of CD4+ and CD8+ T cells and TNF-alpha production in a dose-dependent manner. Dexmedetomidine 18-33 tumor necrosis factor Mus musculus 91-100 35412062-11 2022 DEX treatment or miR-329-3p downregulation caused attenuated cognitive dysfunction and microglia activation as well as reduced IL-1beta, IL-6, and TNF-alpha levels in the hippocampus of the postoperative NCD mice. Dexmedetomidine 0-3 tumor necrosis factor Mus musculus 147-156 35538293-14 2022 And miR-665 knockdown attenuated the effect of DEX on inflammation damage (the levels of TNF-alpha, IL-1beta and IL-6 increased 1.36 times, 1.31 times, 1.43 time, respectively, and IL-10 decreased 1.68 times) and apoptosis from 17 to 25% (P < 0.01). Dexmedetomidine 47-50 tumor necrosis factor Mus musculus 89-98 35502244-10 2022 In cultured alveolar macrophages, Dex reduced LPS-mediated expression of IL-1, -6 and TNF-alpha receptors while promoting alveolar macrophages differentiation towards a M2 anti-inflammatory phenotype. Dexmedetomidine 34-37 tumor necrosis factor Mus musculus 86-95 33220278-9 2021 DEX inhibited LPS-induced TNFalpha, IL-6, and PGE2 productions and COX-2 mRNA expression, and the effects of DEX were reversed by yohimbine. Dexmedetomidine 0-3 tumor necrosis factor Mus musculus 26-34 33220278-11 2021 Furthermore, T0070907 reversed the anti-inflammatory effects of DEX on TNFalpha and IL-6 productions in the cells. Dexmedetomidine 64-67 tumor necrosis factor Mus musculus 71-79 33179100-12 2021 Moreover, dexmedetomidine significantly decreased the levels of TNF-alpha, IL-1beta and IL-6 in the hippocampus. Dexmedetomidine 10-25 tumor necrosis factor Mus musculus 64-73 32145512-9 2020 In vitro, dexmedetomidine pretreatment promoted BMDMs M2 activation, as evidenced by increased Arg1 and Mrc1 gene induction, decreased iNOS gene induction, inhibited phosphorated-signal transducer and activator of transcription 1 (p-STAT1) but enhanced p-STAT6 expression, much lower levels of proinflammatory TNF-alpha and IL-6, and higher levels of anti-inflammatory IL-10 cytokine secretion. Dexmedetomidine 10-25 tumor necrosis factor Mus musculus 310-319 31823113-12 2020 Pretreatment with dexmedetomidine attenuated LPS-elicited changes in p-ERK, iNOS, TNF-alpha, NO, CD206 and IL-10 levels in BV2 cells. Dexmedetomidine 18-33 tumor necrosis factor Mus musculus 82-91 31954762-9 2020 We further confirmed that DEX pretreatment reversed the EtOH-induced microglia activation in the DG as well as the upregulation of the hippocampal TNFalpha, MCP-1, IL-6, and IL-1beta mRNA levels. Dexmedetomidine 26-29 tumor necrosis factor Mus musculus 147-155 31823113-13 2020 However, co-treatment with dexmedetomidine and LM22B-10, an agonist of ERK, reversed dexmedetomidine-elicited changes in p-ERK, iNOS, TNF-alpha, NO, CD206 and IL-10 levels in LPS-exposed BV2 cells. Dexmedetomidine 27-42 tumor necrosis factor Mus musculus 134-143 31823113-13 2020 However, co-treatment with dexmedetomidine and LM22B-10, an agonist of ERK, reversed dexmedetomidine-elicited changes in p-ERK, iNOS, TNF-alpha, NO, CD206 and IL-10 levels in LPS-exposed BV2 cells. Dexmedetomidine 85-100 tumor necrosis factor Mus musculus 134-143 29545877-8 2018 The content of tumor necrosis factor-alpha, interleukin-6 and albumin in bronchoalveolar fluid and MPO in lung tissue was significantly decreased in the 3-MA and DEX groups compared with the model group (P<0.05). Dexmedetomidine 162-165 tumor necrosis factor Mus musculus 15-42 31682847-10 2019 The H3K4me3 enrichment of the multiple genes associated with inflammatory cytokines such as TNF-alpha, NOS2 and CCL2 increased in AKI model, but decreased upon DEX or KDM5A-IN-1 treatment. Dexmedetomidine 160-163 tumor necrosis factor Mus musculus 92-101 31185237-8 2019 Dex treatment reduced the levels of ROS, MDA, TNF-alpha and IL-1beta in the entire middle cerebral artery territory of diabetic mice subjected to MCAO/R, as well as in primary culture of mouse hippocampal neurons stimulated with 50 mM glucose and oxygen glucose deprivation/reperfusion. Dexmedetomidine 0-3 tumor necrosis factor Mus musculus 46-55 30071186-7 2018 RESULTS: We found that Dex exerted a potent anti-inflammatory effect by reducing the expression of M1 marker genes such as tumor necrosis factor alpha (P < 0.05), interleukin-1beta (IL-1beta) (P < 0.001) and IL-6 (P < 0.001). Dexmedetomidine 23-26 tumor necrosis factor Mus musculus 123-150 31030092-6 2019 Pre-treatment with DEX also inhibited the release of TNF-alpha and suppressed the phosphorylation of c-jun-N-terminal kinase (JNK) in mice exposed to LPS/D-Gal. Dexmedetomidine 19-22 tumor necrosis factor Mus musculus 53-62 29269298-9 2018 RESULTS: Dexmedetomidine at 20 mug/kg significantly attenuated pancreatic pathological injury, reduced serum levels of amylase, lipase, IL-1beta, IL-6, and tumor necrosis factor (TNF)-alpha, and decreased the expression of MPO in pancreatic tissue in both mouse models of pancreatitis. Dexmedetomidine 9-24 tumor necrosis factor Mus musculus 156-189 28224201-11 2017 DEX suppressed the infiltration of macrophages and T cells into the kidneys following cisplatin treatment, which was involved in the inhibition of NF-kappaB activation and decreased expression of TNF-alpha, IL-1beta, IL-6, and MCP-1. Dexmedetomidine 0-3 tumor necrosis factor Mus musculus 196-205 29351316-12 2018 The mRNA expression of TNF-alpha, MCP-1, indoleamine 2, 3 dioxygenase (IDO), caspase-3, and iNOS were increased in the brain of LPS-challenged mice, which were reduced by Dex but not vehicle. Dexmedetomidine 171-174 tumor necrosis factor Mus musculus 23-32 28784305-8 2017 After hepatic I/R injury, WT and NLRC5-/- mice pre-treated with DEX exhibited attenuated histological disruption, and reduced pro-inflammatory mediators, including tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-6, IL-1beta and inducible nitric oxide synthase (iNOS), which was associated with the inactivated NF-kappaB pathway. Dexmedetomidine 64-67 tumor necrosis factor Mus musculus 164-191 28784305-8 2017 After hepatic I/R injury, WT and NLRC5-/- mice pre-treated with DEX exhibited attenuated histological disruption, and reduced pro-inflammatory mediators, including tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-6, IL-1beta and inducible nitric oxide synthase (iNOS), which was associated with the inactivated NF-kappaB pathway. Dexmedetomidine 64-67 tumor necrosis factor Mus musculus 193-202 28555511-5 2017 We found that dexmedetomidine dose-dependently inhibited the production of tumor necrosis factor (TNF)-alpha and interleukin (IL)-6 in the pouch and decreased the number of white blood cells (WBC) recruited into the pouch. Dexmedetomidine 14-29 tumor necrosis factor Mus musculus 75-108 26702389-6 2015 Our results provided evidence that Dex treatment attenuated LPS-activated NF-kappaB p65 activation, as well as the production of tumor necrosis factor-alpha, interleukin-6, and interleukin-1beta at the level of both mRNA and protein in spleen. Dexmedetomidine 35-38 tumor necrosis factor Mus musculus 129-156 28247333-5 2017 Our results indicate that treatment with 6-OHDA promotes microglial polarization toward the M1 state in BV2 microglia cells by increasing the release of interleukin (IL)-6, IL-1beta, or tumor necrosis factor-alpha, which can be prevented by pretreatment with DEX. Dexmedetomidine 259-262 tumor necrosis factor Mus musculus 186-213 28139820-3 2016 Our study was aimed to explore the effects of DEX on tumor necrosis factor-alpha (TNF-alpha) expression in unmethylated CpG DNA-challenged microglia. Dexmedetomidine 46-49 tumor necrosis factor Mus musculus 82-91 28139820-7 2016 And while BV2 microglia was stimulated by ODN1668 for different time, TNF-alpha was increased in mRNA and protein levels but the effect was attenuated by DEX via decreasing phosphorylated AKT and ERK. Dexmedetomidine 154-157 tumor necrosis factor Mus musculus 70-79 28173746-10 2017 Dex could significantly decrease brain inflammation and oxidative stress by decreasing the levels of TNF-alpha, IL-1beta, MDA and ROS, and ameliorate neurodegenerative changes. Dexmedetomidine 0-3 tumor necrosis factor Mus musculus 101-110 26911944-18 2016 (3) The results of ELISA showed that the levels of TNF-alpha and NSE in serum were significantly increased in LPS groups as compared with that in NS group, and the levels of TNF-alpha and NSE were significantly decreased in DEX+LPS group. Dexmedetomidine 224-227 tumor necrosis factor Mus musculus 51-60 26911944-18 2016 (3) The results of ELISA showed that the levels of TNF-alpha and NSE in serum were significantly increased in LPS groups as compared with that in NS group, and the levels of TNF-alpha and NSE were significantly decreased in DEX+LPS group. Dexmedetomidine 224-227 tumor necrosis factor Mus musculus 174-183 24803295-11 2014 Preemptive administration of dexmedetomidine significantly attenuated the cytokine response after lipopolysaccharide (LPS) induced endotoxemia (TNF-alpha, IL-1beta, IL-6, P<0.01, respectively). Dexmedetomidine 29-44 tumor necrosis factor Mus musculus 144-153 26211495-8 2015 The results showed that pretreatment with Dex considerably reduced neutrophil infiltration and pulmonary edema, and significantly reduced protein concentrations in the BALF, as well as suppressed LPS-induced elevation of proinflammatory cytokines (TNF-alpha and IL-1beta) in the serum. Dexmedetomidine 42-45 tumor necrosis factor Mus musculus 248-257 23850057-15 2014 Treatment with dexmedetomidine significantly attenuated microglial activation and proinflammatory cytokine production in vitro with a greater than twofold reduction in tumor necrosis factor-alpha. Dexmedetomidine 15-30 tumor necrosis factor Mus musculus 168-195 24445644-9 2014 Dexmedetomidine significantly inhibited all increases in paw volume, leukocytes, and production of TNF-alpha and COX-2. Dexmedetomidine 0-15 tumor necrosis factor Mus musculus 99-108